The Journal of hospital infection
-
Randomized Controlled Trial Clinical Trial
Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial.
It has been suggested that central venous catheters impregnated with antiseptics such as chlohexidine and silver-sulfadiazine reduce the risk of catheter-related bacteraemia in intensive care patients. Patients suffering from haematologic malignancy treated by chemotherapy through a central venous catheter are at even greater risk of catheter-related bacteraemia. A prospective double-blind randomized controlled trial was performed in order to investigate the effectiveness of chlorhexidine and silver-sulfadiazine impregnated catheters (CH-SS) in these patients. ⋯ There was no statistically significant different between the overall rates of bloodstream infection for impregnated and non-impregnated catheters (14.5 vs. 16.3%). The incidence of catheter-related infection was also similar in both groups (5 vs. 4.4%) and there was no difference in the time of the onset of bacteraemia in the two groups. It is concluded that the use of CH-SS catheters in patients with haematologic malignancy reduces neither the overall risk of bloodstream infection, nor the catheter-related infection rate, nor the delay for the occurrence of infection.
-
Several reports have documented the presence of vancomycin-resistant enterococci (VRE) in the stools of asymptomatic individuals from the community who have neither recently been in hospital nor received antibiotics. Such findings were contrary to the then existing perception of VRE as a strictly hospital-acquired infection of debilitated and immunocompromised patients on specialized units. Community-acquired infections with VRE are extremely rare but those that do occur may be conspicuous because of their serious nature, for example, endocarditis. ⋯ As long ago as 1969, the Swann report declared that an antibiotic of medical importance should not be used as a growth promoter in animal feeds. The vasy array of antibiotics now being used in animal husbandry and fish-farming, and the cross-resistance of some antibiotics to their medically important counterparts is a real cause for concern. The emergence of multi-resistant enterococci causing human infections and the possibility of the transfer of the VanA gene from VRE to methicillin-resistant Staphylococcus aureus (MRSA) emphasizes the importance of this problem.